EA
SYRE icon

Emerald Advisers’s Spyre Therapeutics SYRE Stock Holding History

Emerald Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4M Sell
567,430
-45,935
-7% -$3.35M 1.19% 27
2026
Q1 		$30.9M Sell
613,365
-22,744
-4% -$857K 0.98% 38
2025
Q4 		$20.8M Buy
636,109
+87,397
+16% +$2.28M 0.64% 72
2025
Q3 		$9.2M Sell
548,712
-17,151
-3% -$280K 0.29% 104
2025
Q2 		$8.47M Buy
565,863
+18,036
+3% +$267K 0.31% 100
2025
Q1 		$8.84M Buy
547,827
+1,036
+0.2% +$21.6K 0.4% 87
2024
Q4 		$12.7M Buy
546,791
+254,222
+87% +$7.45M 0.49% 78
2024
Q3 		$8.6M Buy
+292,569
New +$8.15M 0.33% 97

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Emerald Advisers's SYRE Position: Q2 2026 in Review

Emerald Advisers reduced its Spyre Therapeutics (SYRE) stake by 7.5% in Q2 2026, selling an estimated $3.35M and leaving 567,430 shares worth $50.4M. The position accounts for 1.19% of the portfolio, ranked #27.

Emerald Advisers first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Emerald Advisers held 567,430 shares of Spyre Therapeutics worth $50.4M as of Q2 2026.
  • Emerald Advisers sold 45,935 Spyre Therapeutics shares in Q2 2026, an estimated $3.35M.
  • Spyre Therapeutics made up 1.19% of Emerald Advisers's portfolio in Q2 2026, its #27 holding.
  • Emerald Advisers first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.